Skip to main content
GSK
NYSE Life Sciences

GSK's Jideytro Wins FDA Approval for ROS1-Positive Lung Cancer, First in Class from Nuvalent Deal

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$50.935
Mkt Cap
$101.379B
52W Low
$36.34
52W High
$61.695
52W Position info
40% above low
Off High info
17% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

GSK sits 40% above its 52-week low of $36.34.

Summary

GSK's Jideytro (zidesamtinib) received FDA approval for previously treated ROS1-positive NSCLC, the first approval from the recently completed Nuvalent acquisition. The drug showed a 44% response rate with durable benefits, arriving two months ahead of schedule and strengthening GSK's growing oncology portfolio.


Key Events · Product Development and Regulatory · GSK

  • FDA Approval of Jideytro

    Jideytro (zidesamtinib) approved for adults with previously treated ROS1-positive NSCLC, two months ahead of the September 18, 2026 target action date.

  • Efficacy and Safety Data

    In 117 patients, objective response rate was 44% (95% CI: 34-53%); duration of response at 6 and 12 months was 82% and 69%, respectively. Most common adverse reactions (≥15%) included oedema, peripheral neuropathy, constipation, fatigue, and dyspnoea.

  • First Lung Cancer Approval

    This is GSK's first approved medicine in lung cancer, derived from the recently completed $10.6 billion Nuvalent acquisition, validating the deal's strategic rationale.

  • Pipeline Momentum

    Another Nuvalent asset, neladalkib (NVL-655) for ALK-altered NSCLC, is under FDA review with a target decision date of November 27, 2026; NVL-330 for HER2-altered NSCLC is also in development.


Analysis · GSK · Life Sciences

The FDA approved GSK's Jideytro (zidesamtinib) for previously treated ROS1-positive non-small cell lung cancer, marking the company's first lung cancer drug and the first approval from the $10.6 billion Nuvalent acquisition completed just last week. The approval came two months ahead of the September target date, with compelling efficacy data — a 44% objective response rate and durable responses lasting beyond a year in many patients. This validates GSK's oncology strategy and the Nuvalent deal, with another Nuvalent asset (neladalkib) under FDA review for November 2026. The drug addresses a clear unmet need in a younger patient population often resistant to existing therapies, and its brain-penetrant design tackles a key limitation of current treatments.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 52.5% of the 204 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.68%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GSK was trading at $50.94 on NYSE in the Life Sciences sector, with a market capitalization of approximately $101.4B. The 52-week trading range was $36.34 to $61.70. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GSK - Latest Insights

GSK
Oct 28, 2026, 11:45 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $48.75
Real-time Price: $51.59 info
Change: +$2.84 (+6%) info
Market Cap: $102.622B info
GSK
Oct 28, 2026, 10:45 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $49.08
Real-time Price: $51.59 info
Change: +$2.51 (+5%) info
Market Cap: $102.622B info
GSK
Oct 28, 2026, 3:42 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $51.20
Real-time Price: $51.59 info
Change: +$0.390 (+0.76%) info
Market Cap: $102.622B info
GSK
Oct 26, 2026, 12:16 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $51.12
Real-time Price: $51.59 info
Change: +$0.475 (+0.93%) info
Market Cap: $102.622B info
GSK
Oct 26, 2026, 6:51 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $51.04
Real-time Price: $51.59 info
Change: +$0.550 (+1%) info
Market Cap: $102.622B info